AnnJi Investigational Site
Los Alamitos, California, 90720, United States
Location status: Recruiting
NCT Number: NCT07549919
This is a Phase 1, randomized, single-dose, open-label, two-way crossover study to evaluate the effect of food on AJ201, and to evaluate the safety, tolerability, and pharmacokinetics of AJ201 in Japanese and White healthy male participants.
Interested in participating?
Request Info18 year–55 year
Male
Interventional
Phase 1
Los Alamitos, California, 90720, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
All participants are planned to be administered a single dose of AJ201 for each period (fed and fasted).
Time frame: Pre-dose to Day 6
AUC0-24hr: Area under the concentration-time curve from zero to 24 hours under fasting and fed conditions
Time frame: Pre-dose to Day 6
AUC0-last: Area under the concentration-time curve from zero to the last observed concentration under fasting and fed conditions
Time frame: Pre-dose to Day 6
AUC0-inf: Area under the concentration-time curve from time zero to infinity (extrapolated) under fasting and fed conditions
Time frame: Pre-dose to Day 6
Cmax: Maximal observed concentration under fasting and fed conditions
Time frame: Pre-dose to Day 6
Tmax: Time when the maximal concentration is observed under fasting and fed conditions
Time frame: Pre-dose to Day 6
Residual area: Percentage of AUC0-inf due to extrapolation from the time of the last observed concentration to infinity, calculated as
[1 - (AUC0-last/AUC0-inf)] x 100 under fasting and fed conditions
Time frame: Pre-dose to Day 6
Tlag: Time of observation prior to the first observation with a measurable (non-zero) concentration under fasting and fed conditions
Time frame: Pre-dose to Day 6
T½ el: Terminal elimination half-life under fasting and fed conditions
Time frame: Pre-dose to Day 6
Kel: Terminal elimination rate constant under fasting and fed conditions
Time frame: Pre-dose to Day 6
Cl/F: Apparent clearance under fasting and fed conditions
Time frame: Pre-dose to Day 6
Vz/F: Apparent volume of distribution under fasting and fed conditions
Time frame: Pre-dose to Day 7
Ae0-24hr: Cumulative urinary excretion from time zero to 24 hours, calculated as the sum of the amounts excreted over each collection interval under fasting and fed conditions
Time frame: Pre-dose to Day 7
Ae0-48hr: Cumulative urinary excretion from time zero to 48 hours, calculated as the sum of the amounts excreted over each collection interval under fasting and fed conditions
Time frame: Pre-dose to Day 7
Ae0-last: Cumulative urinary excretion from time zero to the last observed concentrations, calculated as the sum of the amounts excreted over each collection interval under fasting and fed conditions
Time frame: Pre-dose to Day 7
Rmax: Maximal rate of urinary excretion, calculated by dividing the amount of drug excreted in each collection interval by the time over which it was collected under fasting and fed conditions
Time frame: Pre-dose to Day 7
TRmax: Time of maximal urinary excretion, calculated as the midpoint of the collection interval during which Rmax occurred under fasting and fed conditions
Time frame: Pre-dose to Day 7
ClR: Renal clearance, calculated as Ae0-24hr /AUC0-24hr under fasting and fed conditions
Time frame: Baseline to Day 12
Incidence and proportion of volunteers with AEs, including TEAEs and SAEs
Contact information is provided by the study sponsor or research team.
AnnJi Pharmaceutical Co., Ltd.
Industry
A Phase 1, Randomized, Single-dose, Open-label, Two-way, Crossover Study to Evaluate the Effect of Food on AJ201, and to Evaluate the Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07361120
Fertility, Fertility, Male
Maribyrnong, Victoria, Australia
View Trial DetailsNCT07036458
Healthy Male Adults
Nottingham, United Kingdom
View Trial DetailsNCT05134428
Healthy Male Adults, Male Contraception
Wollongong, New South Wales, Australia
View Trial DetailsNCT06923839
Healthy Male Adults
Hellerup, Denmark
View Trial Details